PLAUR and cancer: If a cancer tissue exhibits a predominant, homogeneous TIS-associated marker following senescence-inducing treatment, a CAR-T or CAR-NK approach with a TIS senoantigen (e.g., uPAR)-specific single-chain variable fragment (scFv) domain should enable a single-antigen targeting strategy with high expected efficacy.